James Largent Biography and Net Worth

Director of Alimera Sciences


James R. Largent has been a member of our board of directors since 2011 and became chairman on May 6, 2015, a position he held until December 2018. Mr. Largent has worked extensively within the medical industry. He most recently served as a medical and pharmaceutical consultant, including work with the U.S. ophthalmic device company, Eyeonics Inc. Also in his role as a consultant, he assisted a multinational pharmaceutical and medical device company in the evaluation of strategic targets. Prior to this, Mr. Largent served in various senior management positions at Allergan, Inc., including as vice president of strategic planning where he fostered licensing deals to build product pipelines. Earlier in his career, he was vice president of strategic marketing at Allergan Medical Optics, Inc. Mr. Largent also held positions of increasing responsibility in the marketing and sales departments at Allergan and Pharmacia Ophthalmics. In addition to serving on our board of directors, Mr. Largent is on the board of directors of SOLX Inc., a privately held company focused on the management and surgical treatment of glaucoma. He previously served on the board of directors of Tear Science, Inc., a privately held developer of diagnostic and therapeutic devices for the treatment of patients with dry eye disease. Mr. Largent earned a B.A. in chemistry and an M.B.A., both from the University of California, Irvine.

What is James R. Largent's net worth?

The estimated net worth of James R. Largent is at least $10,020.00 as of November 19th, 2019. Mr. Largent owns 3,000 shares of Alimera Sciences stock worth more than $10,020 as of April 19th. This net worth evaluation does not reflect any other assets that Mr. Largent may own. Learn More about James R. Largent's net worth.

How do I contact James R. Largent?

The corporate mailing address for Mr. Largent and other Alimera Sciences executives is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. Alimera Sciences can also be reached via phone at (678) 990-5740 and via email at [email protected]. Learn More on James R. Largent's contact information.

Has James R. Largent been buying or selling shares of Alimera Sciences?

James R. Largent has not been actively trading shares of Alimera Sciences over the course of the past ninety days. Most recently, on Wednesday, November 3rd, James R. Largent bought 10,000 shares of Alimera Sciences stock. The stock was acquired at an average cost of $4.31 per share, with a total value of $43,100.00. Learn More on James R. Largent's trading history.

Who are Alimera Sciences' active insiders?

Alimera Sciences' insider roster includes Philip Ashman (COO), Richard Eiswirth, Jr. (CEO), John Jones (CFO), and James Largent (Director). Learn More on Alimera Sciences' active insiders.

Are insiders buying or selling shares of Alimera Sciences?

During the last year, Alimera Sciences insiders bought shares 2 times. They purchased a total of 1,980,901 shares worth more than $4,346,041.70. The most recent insider tranaction occured on September, 14th when Major Shareholder Caligan Partners Lp bought 579,000 shares worth more than $1,962,810.00. Insiders at Alimera Sciences own 31.4% of the company. Learn More about insider trades at Alimera Sciences.

Information on this page was last updated on 9/14/2023.

James R. Largent Insider Trading History at Alimera Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/3/2021Buy10,000$4.31$43,100.00View SEC Filing Icon  
11/19/2019Buy3,000$5.11$15,330.003,000View SEC Filing Icon  
See Full Table

James R. Largent Buying and Selling Activity at Alimera Sciences

This chart shows James R Largent's buying and selling at Alimera Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Alimera Sciences Company Overview

Alimera Sciences logo
Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Read More

Today's Range

Now: $3.34
Low: $3.33
High: $3.70

50 Day Range

MA: $3.73
Low: $3.25
High: $4.21

2 Week Range

Now: $3.34
Low: $1.56
High: $4.38

Volume

48,043 shs

Average Volume

78,081 shs

Market Capitalization

$174.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18